# Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium

> **NCT03328312** · EARLY_PHASE1 · UNKNOWN · sponsor: **Iuliu Hatieganu University of Medicine and Pharmacy** · enrollment: 90 (estimated)

## Conditions studied

- Incidence of Postoperative Residual Curarization

## Interventions

- **DRUG:** Sugammadex
- **DRUG:** neostigmine+atropine
- **DRUG:** neostigmine+atropine+sugammadex

## Key facts

- **NCT ID:** NCT03328312
- **Lead sponsor:** Iuliu Hatieganu University of Medicine and Pharmacy
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-01
- **Primary completion:** 2018-03-01
- **Final completion:** 2018-06-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2017-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03328312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03328312, "Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03328312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*